Turakitwanakan Wanpen, Pongpaplud Patirop, Kitporntheranunt Maethaphan
J Med Assoc Thai. 2017 Nov;99 Suppl 8:S171-S178.
Major depressive disorder (MDD) is the important cause of disability in the world. Major depressive patients that are not respond to the first and second drugs are about 67% and 33%, respectively. Therefore the effective treatment is urgently needed.
To examine the effect of Buddhist mindfulness meditation combined with standard treatment on depression and quality of life in major depressive patient compared to the control group.
It was a quasi experimental study. The subjects with age ranged 20-70 years old and had Thai Hamilton rating scale for depression 13-29 scores were divided in two groups, each group contained 30 persons. The intervention was Buddhist mindfulness meditation which meditated everyday at least 5 days/week, 15 minutes each time, for six weeks. Both groups were treated with standard treatment. All subjects were tested using Thai Hamilton rating scale for depression, and WHOQOL-BREF-THAI questionnaire at baseline and every week for six weeks. Compare the result of Buddhist mindfulness meditation by independent t-test and Chi-square.
The difference between the average of Thai Hamilton rating scale for depression (17.33+5.22 in meditation group and 17.67+6.33 in control group) and WHOQOL-BREF-THAI questionnaire (29.97+15.95 in meditation group and 31.33+12.12 in control group) before and after meditation was not statistically significantly among the two groups (p>0.05). However, it found that at the 6th week, 28 patients from the meditation group (93.3%) and 22 patients (73.3%) from the nonmeditating group improved from depression. When examining by the Chi-square, the meditating group had a statistically significantly different in the number of patients that improved from depression (p-value = 0.04).
At the 6th week of Buddhist mindfulness meditation, significant number of patients were improved from depression. Thus, Buddhist mindfulness meditation should be included in the treatment of depression.
重度抑郁症(MDD)是全球致残的重要原因。对第一种和第二种药物无反应的重度抑郁症患者分别约为67%和33%。因此,迫切需要有效的治疗方法。
与对照组相比,研究佛教正念冥想联合标准治疗对重度抑郁症患者抑郁症状及生活质量的影响。
这是一项准实验研究。年龄在20 - 70岁、泰国版汉密尔顿抑郁量表评分为13 - 29分的受试者被分为两组,每组30人。干预措施为佛教正念冥想,每周至少5天,每天冥想15分钟,共持续六周。两组均接受标准治疗。所有受试者在基线及六周内每周使用泰国版汉密尔顿抑郁量表和世界卫生组织生存质量简表(WHOQOL - BREF - THAI)进行测试。采用独立样本t检验和卡方检验比较佛教正念冥想的效果。
冥想组和对照组在冥想前后的泰国版汉密尔顿抑郁量表平均分(冥想组为17.33 + 5.22,对照组为17.67 + 6.33)以及WHOQOL - BREF - THAI问卷平均分(冥想组为29.97 + 15.95,对照组为31.33 + 12.12)差异无统计学意义(p > 0.05)。然而,在第6周时发现,冥想组有28名患者(93.3%)抑郁症状改善,非冥想组有22名患者(73.3%)抑郁症状改善。经卡方检验,冥想组抑郁症状改善患者数量有统计学显著差异(p值 = 0.04)。
在佛教正念冥想第6周时,大量患者抑郁症状得到改善。因此,佛教正念冥想应纳入抑郁症的治疗。